SE1064009T4 - Use of iris extract and Cimicifuga racemosa extract and tectorigenin as an estrogenic organ selective drug without uterotropic action - Google Patents

Use of iris extract and Cimicifuga racemosa extract and tectorigenin as an estrogenic organ selective drug without uterotropic action

Info

Publication number
SE1064009T4
SE1064009T4 SE99913282T SE99913282T SE1064009T4 SE 1064009 T4 SE1064009 T4 SE 1064009T4 SE 99913282 T SE99913282 T SE 99913282T SE 99913282 T SE99913282 T SE 99913282T SE 1064009 T4 SE1064009 T4 SE 1064009T4
Authority
SE
Sweden
Prior art keywords
extract
tectorigenin
estrogenic
cimicifuga racemosa
iris
Prior art date
Application number
SE99913282T
Other languages
Swedish (sv)
Other versions
SE1064009T3 (en
SE1064009T5 (en
Inventor
Wolfgang Wuttke
Hubertus Jarry
Volker Christoffel
Barbara Spengler
Michael Popp
Original Assignee
Bionorica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7861630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE1064009(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bionorica Ag filed Critical Bionorica Ag
Publication of SE1064009T3 publication Critical patent/SE1064009T3/en
Publication of SE1064009T5 publication Critical patent/SE1064009T5/en
Publication of SE1064009T4 publication Critical patent/SE1064009T4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to the utilization of extracts from iris plants, cimicifuga racemosa and tectorigenin as an estrogen-like organ-selective medicament for selectively treating and/or for the prophylaxis of cardiovascular diseases, especially arteriolosclerosis, osteoporosis and climacteric symptoms, for example, for preventing or alleviating hot flashes. Virtually no uterotropic effects are observed when using said abstracts.
SE99913282T 1998-03-19 1999-03-19 Use of iris extract and Cimicifuga racemosa extract and tectorigenin as an estrogenic organ selective drug without uterotropic action SE1064009T4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19812204A DE19812204A1 (en) 1998-03-19 1998-03-19 Use of extracts from Cimicifuga racemosa and Belamcanda sinensis as an estrogen-like organ-selective drug without uterotropic effects

Publications (3)

Publication Number Publication Date
SE1064009T3 SE1064009T3 (en) 2003-01-21
SE1064009T5 SE1064009T5 (en) 2003-04-15
SE1064009T4 true SE1064009T4 (en) 2008-09-23

Family

ID=7861630

Family Applications (1)

Application Number Title Priority Date Filing Date
SE99913282T SE1064009T4 (en) 1998-03-19 1999-03-19 Use of iris extract and Cimicifuga racemosa extract and tectorigenin as an estrogenic organ selective drug without uterotropic action

Country Status (21)

Country Link
EP (1) EP1064009B2 (en)
JP (2) JP2002506827A (en)
KR (1) KR100623333B1 (en)
CN (2) CN100581541C (en)
AT (1) ATE225182T1 (en)
AU (1) AU755900C (en)
BR (1) BR9908256A (en)
CA (1) CA2321444C (en)
CZ (1) CZ292684B6 (en)
DE (2) DE19812204A1 (en)
DK (1) DK1064009T4 (en)
ES (1) ES2184427T5 (en)
HK (1) HK1035660A1 (en)
HU (1) HU227694B1 (en)
MX (1) MXPA00007986A (en)
PL (1) PL194096B1 (en)
PT (1) PT1064009E (en)
RU (2) RU2263505C2 (en)
SE (1) SE1064009T4 (en)
TR (1) TR200002686T2 (en)
WO (1) WO1999047149A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000302667A (en) * 1999-04-23 2000-10-31 Kobe Tennenbutsu Kagaku Kk Accelerator for ample breasts
AU7311501A (en) * 2000-06-29 2002-03-22 Quick Med Technologies Inc Cosmetic composition and method
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
DE10054641A1 (en) 2000-11-03 2002-05-16 Schaper & Bruemmer Gmbh Use of a preparation of Cimicifuga racemosa
DE10123503A1 (en) * 2001-05-15 2002-11-21 Bionorica Ag Use of Belamcanda chinensis extract, or its active ingredient, for treating sex hormone-dependent urogenital disorders and prostatic hyperplasia
DE10127897B4 (en) * 2001-06-08 2006-04-20 Bionorica Ag Coated tablet with dry plant extracts
DE10146159A1 (en) * 2001-09-19 2003-04-10 Bionorica Ag Use of extracts from Cimicifuga species as an organ-selective drug for the treatment of sex hormone-dependent diseases of the urogenital tract
EP1325681A1 (en) * 2001-12-11 2003-07-09 Société des Produits Nestlé S.A. Composition for promotion of bone growth and maintenance of bone health
DE10206390A1 (en) * 2002-02-15 2003-08-28 Bionorica Ag Use of phytoestrogen-containing extracts that selectively modulate the estrogen receptor beta
JP4605984B2 (en) * 2002-12-20 2011-01-05 アサヒビール株式会社 Stress relieving agent
ATE427944T1 (en) * 2003-05-15 2009-04-15 Chengdu Dikang Pharmaceutical ISOFLAVONE DERIVATIVES OF TECTORIDINE, THEIR PRODUCTION AND ANTIVIRAL MEDICATIONS CONTAINING SAME AS ACTIVE INGREDIENTS
EP1588739A1 (en) * 2004-04-23 2005-10-26 Schaper & Brümmer Gmbh & Co. Kg Composition comprising a combination of calcium, Cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement
EP1591143A1 (en) * 2004-04-26 2005-11-02 Schaper & Brümmer Gmbh & Co. Kg Composition comprising a combination of Calcium, Cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement
US7887851B2 (en) 2004-06-07 2011-02-15 Kao Corporation Aromatase activator
CN100381435C (en) * 2005-03-24 2008-04-16 深圳海王药业有限公司 Extractive of general flavone from blackberry lily, preparation method and application in preparing medication
EP1745796A1 (en) 2005-07-19 2007-01-24 Bionorica Research GmbH Compound preparation for treating prostate carcinoma
CN101057854B (en) * 2006-05-31 2010-05-12 南京大学 Application of cycloartane type triterpenoids compound of cimicifuga rhizome for anti-osteoporosis and menopausal syndrome
DE102007044916A1 (en) 2007-09-19 2009-04-23 Bionorica Ag Cosmetic or dermatological composition for topical use
KR100928013B1 (en) * 2008-01-25 2009-11-24 이화여자대학교 산학협력단 Method for improvement in growth of Echinochola crusgalli using Belamcanda chinensis extract and method for remediation of heavy-metal contaminated soil using the method
CN101797265A (en) * 2010-04-09 2010-08-11 中国人民解放军第二军医大学 Application of belamcanda chinensis total isoflavone or isoflavone compounds in preparing medicaments and food for preventing and treating women's disease
EP2545932A1 (en) 2011-07-12 2013-01-16 Bionorica Se Selected cimicifuga fractions for treating osteoporosis
WO2013007807A1 (en) 2011-07-12 2013-01-17 Bionorica Se Selected cimicifuga fractions for the treatment of osteoporosis
EP2620155A1 (en) 2012-01-30 2013-07-31 Bionorica SE Medicine containing Cimicifuga for use in the treatment of sarcopenia and myocardial weakness
CN102525907B (en) * 2012-02-22 2013-06-05 四川省中医药科学院 Tectorigenin sodium sulfonate injection
CN102631363A (en) * 2012-04-11 2012-08-15 李超生 Application of tectoridin in preparing medicine for preventing osteoporosis
KR20150018831A (en) * 2012-06-22 2015-02-24 골든 바이오테크놀러지 코포레이션 Methods and compositions for treating arteriosclerotic vascular diseases
MX366970B (en) 2012-07-03 2019-08-01 Zeller Max Soehne Ag Novel pharmacological use of cimicifuga extract.
JP2014091706A (en) * 2012-11-02 2014-05-19 Kao Corp Glp-1 secretion promoter
KR101964841B1 (en) * 2017-03-07 2019-08-07 주식회사 엘지생활건강 Composition for relieving menopausal symptom
KR101965849B1 (en) * 2017-03-07 2019-04-04 주식회사 엘지생활건강 Composition for relieving menopausal symptom comprising Tectorigenin 7-O-xylosylglucoside
TWI761372B (en) * 2017-09-22 2022-04-21 日商東洋新藥股份有限公司 combination
EP3906040A1 (en) 2018-12-31 2021-11-10 Max Zeller Söhne AG Combination of cimicifuga and petasites extracts for anticancer therapy and prophylaxis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6330417A (en) * 1986-07-23 1988-02-09 Tsumura Juntendo Inc Anti-allergic agent
WO1997009056A1 (en) * 1995-09-07 1997-03-13 L'oreal Extract of iridaceae and compositions containing such extract
PL327617A1 (en) * 1995-10-23 1998-12-21 Zymogenetics Inc Compositions for and methods of treating osseous insufficiency
JPH09301884A (en) * 1996-05-15 1997-11-25 Ichimaru Pharcos Co Ltd Testosterone 5 alpha-reductase inhibitor containing blackberry lily extract and alpha-hydroxyl acid and its application
JPH107580A (en) * 1996-06-15 1998-01-13 Michio Yoshida Collagenase inhibitor
JP3665848B2 (en) * 1996-09-18 2005-06-29 木村 幸代 Fermented beverage of Himeogi dwarf bulb extract and method for producing the same
DE19652183C1 (en) * 1996-12-14 1998-02-12 Schaper & Bruemmer Gmbh Treating oestrogen-dependent tumour with Cimicifuga racemosa extract

Also Published As

Publication number Publication date
RU2228188C2 (en) 2004-05-10
PL194096B1 (en) 2007-04-30
TR200002686T2 (en) 2000-12-21
ES2184427T3 (en) 2003-04-01
RU2263505C2 (en) 2005-11-10
DK1064009T4 (en) 2008-08-25
ATE225182T1 (en) 2002-10-15
HU227694B1 (en) 2011-12-28
CN100444867C (en) 2008-12-24
HUP0200921A3 (en) 2004-05-28
EP1064009A1 (en) 2001-01-03
ES2184427T5 (en) 2008-12-16
AU755900B2 (en) 2003-01-02
PL342486A1 (en) 2001-06-04
DE19812204A1 (en) 1999-11-04
EP1064009B9 (en) 2003-02-05
CN1293575A (en) 2001-05-02
CA2321444A1 (en) 1999-09-23
PT1064009E (en) 2003-02-28
HUP0200921A2 (en) 2002-12-28
AU755900C (en) 2005-04-21
JP2002506827A (en) 2002-03-05
WO1999047149A1 (en) 1999-09-23
KR100623333B1 (en) 2006-12-05
CN1509712A (en) 2004-07-07
CZ292684B6 (en) 2003-11-12
AU3146699A (en) 1999-10-11
JP2010132699A (en) 2010-06-17
DE59902932D1 (en) 2002-11-07
SE1064009T3 (en) 2003-01-21
HK1035660A1 (en) 2001-12-07
RU2003137324A (en) 2005-06-10
EP1064009B1 (en) 2002-10-02
SE1064009T5 (en) 2003-04-15
BR9908256A (en) 2000-12-12
MXPA00007986A (en) 2002-08-06
EP1064009B2 (en) 2008-07-30
CZ20002810A3 (en) 2000-12-13
DK1064009T3 (en) 2002-11-04
KR20010040829A (en) 2001-05-15
CN100581541C (en) 2010-01-20
CA2321444C (en) 2012-10-02

Similar Documents

Publication Publication Date Title
SE1064009T4 (en) Use of iris extract and Cimicifuga racemosa extract and tectorigenin as an estrogenic organ selective drug without uterotropic action
RU2000126476A (en) APPLICATION OF EXTRACTS OF THE IRIDACEAE AND CIMICIFUGA RACEMOSA AND TECTORIGENIN FAMILY AS AN ORGAN-SELECTIVE MEDICINAL PRODUCT UNDERTAKING WHICH DOES NOT HAVE A UTERETROPHIC EFFECT
DK1370271T3 (en) Process for the preparation of a matrix-containing plant preparation
JP2002506827A5 (en)
TR200002770T2 (en) Treatment of estrogen related disorders
WO2002047706A3 (en) Selective cox-2 inhibition from plant extracts
Lopez‐Jornet et al. Effects of potassium apigenin and verbena extract on the wound healing process of SKH‐1 mouse skin
Sowemimo et al. Anti-inflammatory activity of Markhamia tomentosa (Benth.) K. Schum. Ex Engl. ethanolic leaf extract
NO975858D0 (en) Use of an extract of Cimicifuga racemosa
Kakorin et al. Potential biological activity and chemical composition of Caragana Jubata (pall.) Poir.
Durairaj et al. Antiplatelet activity of white and pink Nelumbo nucifera Gaertn flowers
Gu et al. Phytochemical and biological research of Polygoneae medicinal resources
ATE475455T1 (en) MEDICINE CONTAINING EPIMEDIUM EXTRACT FOR THE TREATMENT OF PROSTATE HYPERPLASIA AND PROSTATITIS
NO975177D0 (en) Pharmaceutical compositions for the treatment of alcohol dependence
BR0209629A (en) Use of extracts and preparations from iridaceae and tectorigenin as an organoselective drug for the treatment of sex hormone-related disorders in the urogenital tract
DE60030786D1 (en) MURRAYA KOENIGII EXTRACTS FOR THE TREATMENT OF ASTHMA
Ruth et al. Antispermatogenic activity of Aspilia africana methanol leaf extract in male Wistar rats.
DE60113418D1 (en) ANTI-CARCINOGENIC ACTIVITY OF HYDROXYLATED CHALCON COMPOUNDS ISOLATED FROM THE LACRICOT ROOT
Basnett et al. A review on medicinal values and pharmacological importance of Moraceae
UA37765A (en) METHOD OF TREATMENT OF PSORIASIS
YU69395A (en) Preparatons based on medical herbs
BG103314A (en) Means for the treatment of tumours
TW200806310A (en) Medical compositions for inhibiting brain tumor
TW200806309A (en) Medical compositions for inhibiting brain tumor
TW200806305A (en) Medical compositions for inhibiting brain tumor